Northwire Canada EditionTuesday, July 14, 2026
Northwire
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Financings

Algernon Health closes second tranche of financing

AGN · Price

Executive Summary

  • Algernon Health Inc. has closed the second tranche of its non-brokered private placement, raising $210,000.
  • The tranche consisted of the sale of 3 million units at a price of $0.07 per unit.
  • Proceeds are designated for advancing the Alzheimer's disease program, opening the first U.S. AD clinic, general and administrative expenses, and working capital.

Key Details

  • Transaction Structure: Non-brokered private placement.
  • Gross Proceeds: $210,000.
  • Units Sold: 3,000,000 units.
  • Issue Price: $0.07 per unit.
  • Finders' Fees: No cash finders' fees were paid for this tranche.
  • Use of Proceeds: Advancing Alzheimer's disease (AD) program, opening the first U.S. AD clinic, general and administrative expenses, and working capital.
  • Securities Terms: Securities are subject to a statutory hold period of four months plus one day from the date of issuance under Canadian securities legislation.
  • Timeline Context: This follows the first tranche, which closed on November 14, 2025, and the initial announcement on November 6, 2025.
Read the original news release →

More from Algernon Health Inc